Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
The first pilot study from India analyzing Covaxin-Covishield mixed doses
Partnering to build biosynthesis processes and a pharmaceutical production platform
Celltrion plans to provide dual treatment options for COVID-19; Regkirona for hospitalised patients and a nebulised cocktail therapy (CT-P63 in combination with Regkirona) for at- home settings
The combination enhances Comar's customer value proposition by adding complementary closure and jar products and related precision mold-making expertise
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults
It will be marketed under the brand name Molunamax
The company will market it under the brand name Molflu
Subscribe To Our Newsletter & Stay Updated
